Drug
Nebicapone clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2005 | 3 |
| 2006 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Carbidopa, levodopa drug combination (2) · Resveratrol (1) · Benserazide, levodopa drug combination (1) · Levodopa (1)
Studies
Open first, then newest update. How each study uses nebicapone is read from its arms, and is right about nine times in ten.
Testing it · 12
- Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedPhase 1Bial - Portela C S.A.NCT02779348Written as BIA 3-202
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedPhase 2Bial - Portela C S.A.NCT03103399Written as Nebicapone
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgCompletedPhase 1Bial - Portela C S.A.NCT03097211Written as Nebicapone
- Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedPhase 2Bial - Portela C S.A.NCT02834507Written as BIA 3-202
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazideCompletedPhase 1Bial - Portela C S.A.NCT02778594Written as BIA 3-202
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaCompletedPhase 1Bial - Portela C S.A.NCT02774564Written as BIA 3-202
- Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02763787Written as BIA 3-202
- Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02772627Written as Nebicapone
- Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT02772614Written as BIA 3-202 (200 mg)
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)CompletedPhase 1Bial - Portela C S.A.NCT02763839Written as BIA 3-202
- Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202CompletedPhase 1Bial - Portela C S.A.NCT02763800Written as BIA 3-202
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)CompletedPhase 1Bial - Portela C S.A.NCT02763852Written as BIA 3-202
Codes
What other systems call nebicapone · ClinicalTrials.gg INT004372
- MeSH (NLM) C433466nebicaponeOne source NLM
- UNII (FDA) NM2KXJ990TNEBICAPONEConfirmed FDA, NLM, Wikidata
- Wikidata Q21547145nebicaponeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83923NebicaponeOne source FDA
- DrugBank DB14849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C433466 | nebicapone | One source NLM |
| UNII (FDA) | NM2KXJ990T | NEBICAPONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21547145 | nebicapone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83923 | Nebicapone | One source FDA |
| DrugBank | DB14849 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.